Sandoz shutters German and Indian production sites

By Fiona BARRY

- Last updated on GMT

Sandoz head Richard Francis spoke during an earnings call this week. (Image: Sandoz/YouTube)
Sandoz head Richard Francis spoke during an earnings call this week. (Image: Sandoz/YouTube)

Related tags Pfizer Teva pharmaceutical industries

Sandoz has revealed it will close three manufacturing sites in Germany and India.

Head of Sandoz Richard Francis told investors this week he made the “difficult decision​” to improve cost efficiency of manufacturing in the “very competitive​” generics sector.

The sites in Gerlingen and Frankfurt, Germany and Turbhe, near Mumbai, India will close by the end of 2016.

Antibiotics and oral

The Gerlingen facility manufactures generic oral solids, including ibuprofen, cetirizine, amlodipine and omeprazole. Frankfurt makes cephalosporin antibiotics, (7-ACA) while Turbhe is an API site for Sandoz’s antibiotics business.

German manufacturing will remain in Europe, with Gerlingen’s production transferred to Sandoz’s Strykow site in Poland and Barleben in Germany. Cephalosporin will move to Sandoz’s giant antibiotics facility in Austria. Turbhe will send its manufacturing to the company’s other Indian sites.

A Sandoz spokesperson told us several hundred jobs will be cut during the moves, “however we are keeping a strong presence in Germany – and India, with jobs also being created elsewhere.​”

Sandoz had a successful Q2, as parent company Novartis revealed this week the generics business saw core operating income of $423m for the quarter,​ a 30% increase on 2014.

In April, the company received FDA approval for Glatopa, the first generic of Teva’s Copaxone for MS. A court ruled this week​ Sandoz may launch Zarxio in September, a biosimilar of Amgen’s Neupogen.

Related news

Show more

Related products

show more

Increasing the Bioavailability of Oncology Drugs

Increasing the Bioavailability of Oncology Drugs

Content provided by Lonza Small Molecules | 13-Nov-2023 | White Paper

Oral tyrosine kinase inhibitors (TKIs) are a class of cancer drugs that can be highly susceptible to issues with solubility in the gastrointestinal tract

Efficient Freezing & Storage of Biopharmaceuticals

Efficient Freezing & Storage of Biopharmaceuticals

Content provided by Single Use Support | 06-Nov-2023 | White Paper

Various options exist for freezing biopharmaceutical bulk material, but selecting the most effective and efficient approach for each cold chain can be...

Manufacturing Drugs with Highly Potent APIs

Manufacturing Drugs with Highly Potent APIs

Content provided by Altasciences | 28-Sep-2023 | White Paper

In this issue of The Altascientist, we examine the critical considerations for the safe and compliant manufacture of drugs with highly potent APIs (HPAPIs),...